(IN BRIEF) Evonik has partnered with Jland Biotech to introduce vegan collagen for cosmetic and personal care applications. Through an investment from Evonik’s Venture Capital group, the collaboration aims to meet the rising demand for sustainable collagen solutions in skincare. … Read the full press release
Posted in Apparel, Fashion & Beauty, Chemicals, Germany, Pharma & Biotech
Tagged Anti-Aging, collagen, color cosmetics, Cosmetic, Evonik, hair care, hydrating creams, Jland Biotech, Johann-Caspar Gammelin, personal care applications, skin care, skin cleansing, skincare, sun care, Vecollage™ Fortify L, vegan collagen, Vegan Society, Yann d'Hervé
(IN BRIEF) Novo Nordisk A/S has announced the date for its Annual General Meeting, scheduled for Thursday, March 21, 2024, at 14:00 CET. The meeting will be held partially electronically, allowing shareholders to participate either in person at Bella Center … Read the full press release
Posted in Business, Denmark, Healthcare, Industrial, Management, Media, News, Pharma & Biotech, Science, Technology
Tagged Andreas Fibig, appointments, Board Re-election, Christina Law, Helge Lund, Henrik Poulsen, Kasim Kutay, Laurence Debroux, leadership, Martin Mackay, Novo Nordisk, Sylvie Grégoire
(IN BRIEF) Evonik has partnered with the University of Mainz to commercialize a new class of polyethylene glycols (PEGs) called randomized polyethylene glycols (rPEGs). These rPEGs will be integrated into Evonik’s specialized lipid platform for drug delivery in nucleic acid-based … Read the full press release
Posted in Chemicals, Germany, Healthcare, Pharma & Biotech, Science, Technology
Tagged Evonik, immunogenicity, lipid, lipid nanoparticle carriers, lipids, LNP carriers, nucleic acid delivery, nucleic acid-based medicines, PEGs, Polyethylene glycols, polymers, Prof. Dr. Holger Frey, randomized polyethylene glycols, rPEG lipids, rPEG-lipids, rPEGs, specialty chemicals, Thomas Riermeier, University of Mainz
(IN BRIEF) AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted by the FDA for the treatment of locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) in patients who have undergone prior … Read the full press release
Posted in Business, Education, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged Adrian Kemp, AstraZeneca, Daiichi Sankyo, datopotamab deruxtecan, Ken Takeshita, NSCLC Treatment, partnership, Susan Galbraith, sustainability
(IN BRIEF) AstraZeneca’s Tagrisso (osimertinib) demonstrates significant improvement in progression-free survival (PFS) for patients with unresectable, Stage III EGFR-mutated non-small cell lung cancer (NSCLC) after chemoradiotherapy (CRT) in the LAURA Phase III trial. The trial, led by Dr. Suresh Ramalingam, … Read the full press release
(IN BRIEF) AstraZeneca’s Tagrisso receives FDA approval for treating adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) following a Priority Review. The decision is based on FLAURA2 Phase III trial results demonstrating that Tagrisso plus … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged Adrian Kemp, AstraZeneca, chemotherapy, Dave Fredrickson, EGFR-mutated lung cancer, FDA, Laurie Ambrose, Pasi A. Jänne, Tagrisso
(IN BRIEF) Almirall, a leading biopharmaceutical company specializing in medical dermatology, has reported its full-year 2023 financial results, showcasing a 4% year-on-year growth in net sales driven by the strong performance of its European Dermatology business. The company’s total EBITDA … Read the full press release
Posted in Business, Economy, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Spain, Technology
Tagged Almirall, Carlos Gallardo, Dermatology, Financial, investment
(IN BRIEF) Almirall S.A., a leading pharmaceutical company specializing in medical dermatology, has finalized an exclusive license agreement with Novo Nordisk for the development and commercialization of NN-8828, an IL-21 blocking monoclonal antibody. This innovative treatment holds potential for various … Read the full press release
Posted in Business, Denmark, Education, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Spain, Technology
Tagged Almirall, Denmark, Dermatology, Dr. Karl Ziegelbauer, IL-21, NN-8828, Novo Nordisk, partnership, sustainability
(IN BRIEF) Japan’s Ministry of Health, Labor and Welfare (MHLW) has authorized the marketing and manufacturing of Dupixent® (dupilumab) for treating chronic spontaneous urticaria (CSU) in patients aged 12 years and older. This approval marks a significant milestone as Japan … Read the full press release
Posted in Business, Education, Financial, France, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged Approval, Chronic Spontaneous Urticaria Treatment, Dupixent, Japan, safety, Sanofi
(IN BRIEF) GSK plc has finalized the acquisition of Aiolos Bio, bolstering its respiratory biologics portfolio with AIO-001, a promising long-acting anti-TSLP monoclonal antibody for treating asthma. AIO-001, set to enter phase II clinical trials, targets severe asthma patients with … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged acquisition, Aiolos Bio, biologics, GSK, respiratory, Tony Wood
(IN BRIEF) From Bonn to Bilbao, Europe’s AI scene is buzzing with innovation. Major players like Deutsche Telekom, Ericsson, and Volkswagen are pushing boundaries through groundbreaking partnerships and integrations. Projects like NextGen are personalizing therapies using AI, while collaborations between … Read the full press release
Posted in Artificial Intelligence (AI), Automotive, Banks, Business, Financial, France, Germany, Healthcare, Internet & Online, Ireland, Netherlands, Pharma & Biotech, Romania, Science, Security & Safety, Spain, Switzerland, Technology, Telecom, United Kingdom
Tagged 5G services, ABB, Accenture, AI, AI IN JAN 2024, AI innovation, AI safety, AI solutions, AI Supercomputers, AI-powered assistants, AI-Powered MBUX Virtual Assistant, Aurora Labs, aws, BBVA, ChatGPT, Deutsche Telekom, Ericsson, Europe's AI scene, Fetch.ai, generative AI, Infineon, Ipsotek, Laura voice assistant, Mercedes-Benz, Meshmind, NextGen, NVIDIA, QuantHealth, Siemens, ŠKODA AUTO, Swisscom, The AI Governance Alliance, Volkswagen
(IN BRIEF) GSK plc has announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for bepirovirsen, an investigational antisense oligonucleotide (ASO) targeting chronic hepatitis B (CHB). The Fast Track designation aims to expedite the development … Read the full press release
Posted in Business, Education, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Bepirovirsen, Chronic Hepatitis B Treatment, FDA Fast Track, GSK
(IN BRIEF) In a Phase III trial conducted in Japan, acoramidis, an investigational treatment for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), demonstrated promising high-level results consistent with the global BridgeBio Pharma, Inc. ATTRibute-CM Phase III trial. The trial in Japan aimed to … Read the full press release
Posted in Business, Education, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Acoramidis, AstraZeneca, Japan, Marc Dunoyer, Professor Yukio Ando, Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM), treatment
(IN BRIEF) Novonesis, the merger of Novozymes and Chr. Hansen, is now officially completed, solidifying its position as a global leader in biosolutions. With over 10,000 employees worldwide and expertise spanning 30 industries, Novonesis aims to provide biosolutions that benefit … Read the full press release
Posted in Business, Denmark, Management, Pharma & Biotech, Technology
Tagged biosolutions, Cees de Jong, Chr. Hansen, Ester Baiget, Novonesis, Novozymes, statutory merger
(IN BRIEF) GSK has received marketing authorization from the European Commission for Omjjara (momelotinib), an oral inhibitor targeting JAK1/JAK2 and activin A receptor type 1 (ACVR1). Omjjara is the first approved treatment in the EU for disease-related splenomegaly (enlarged spleen) … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Francesca Palandri, GSK, Myelofibrosis Treatment, Nina Mojas, Omjjara, splenomegaly
(IN BRIEF) GSK has submitted a regulatory application to the European Medicines Agency (EMA) to expand the use of its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine to adults aged 50-59 who are at increased risk for RSV disease. The … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Adults Aged 50-59, COPD, GSK, NCT05590403, RSV Vaccination, vaccine
(IN BRIEF) E. Merck KG, representing the Merck family’s interests in Merck KGaA, has disclosed the results of its regular board elections. Johannes Baillou, with 30 years of board experience at E. Merck KG, has been elected as Chairman of … Read the full press release
Posted in Business, Germany, Healthcare, Industrial, Management, News, Pharma & Biotech, Science, Technology
Tagged André Wyss, appointment, Carl Christoph Schweickert, Dr Wolfgang Büchele, Dr. Daniel Thelen, Dr. Frank Stangenberg-Haverkamp, Dr. Katharina Kraft, Dr. Susanne Schaffert, E. Merck KG, Family Board Elections, Johannes Baillou, leadership, Merck, Michael Kleinemeier, Professor Dr. Simon Thelen
(IN BRIEF) Merck, a leading science and technology company, has inaugurated the Merck Digital Hub in Singapore, its first digital hub outside of the US and Europe. Supported by the Singapore Economic Development Board (EDB), the hub aims to accelerate … Read the full press release
Posted in Business, Environment, Financial, Germany, Government, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Athinia™, Digital Hub, Healthcare, Laura Matz, Merck, partnership, Semiconductor Innovation, Singapore, Singapore Economic Development Board (EDB), sustainability, Syntropy™, Wan Yee Goh
(IN BRIEF) The U.S. Food and Drug Administration (FDA) has granted approval for Dupixent® (dupilumab) to treat pediatric patients aged 1 to 11 years, weighing at least 15 kg, who suffer from eosinophilic esophagitis (EoE). Dupixent is now the first … Read the full press release
Posted in Business, Education, Financial, France, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged dupilumab, Dupixent, Eosinophilic Esophagitis (EoE) Treatment, FDA approval, George D. Yancopoulos, Naimish Patel, pediatric, Regeneron, Sanofi
(IN BRIEF) BioNTech and Duality Biologics have announced the commencement of a pivotal Phase 3 trial for BNT323/DB-1303, a next-generation antibody-drug conjugate (ADC) targeting the Human Epidermal Growth Factor Receptor 2 (HER2) in metastatic breast cancer. The trial will enroll … Read the full press release
(IN BRIEF) The Japanese Ministry of Health, Labour and Welfare (MHLW) has granted approval for Voydeya (danicopan), a groundbreaking oral Factor D inhibitor, for the treatment of paroxysmal nocturnal haemoglobinuria (PNH). Voydeya is indicated in Japan for use in combination … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca, Innovative Treatment, Japan, Marc Dunoyer, Paroxysmal Nocturnal Haemoglobinuria (PNH), Professor Jun-ichi Nishimura, Voydeya (danicopan)
(IN BRIEF) Basilea Pharmaceutica Ltd (SIX: BSLN) has announced that its partner Knight Therapeutics Inc. (TSX: GUD) exceeded the sales threshold for the antifungal Cresemba (isavuconazole) in Latin America in 2023, triggering the first sales milestone payment for the region. … Read the full press release
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged antifungal, Basilea, Cresemba®, David Veitch, Knight Therapeutics, Latin America, partnership, sustainability
(IN BRIEF) Boehringer Ingelheim has been honored by the Top Employers Institute with a “Global Top Employer” certification for the fourth consecutive year, distinguishing it as one of only 17 globally certified companies. The recognition is attributed to the company’s … Read the full press release
Posted in Awards, Business, Germany, Industrial, Management, News, Pharma & Biotech
Tagged Awards, Boehringer Ingelheim, Employee Development, Global Top Employer, Sven Sommerlatte, wellbeing
(IN BRIEF) Onera Health, a leader in sleep diagnostic and monitoring solutions, has successfully completed a €30 million ($32 million) Series C financing round. The funding was led by EQT Life Sciences and co-led by Gimv, with participation from existing … Read the full press release
(IN BRIEF) Empa researchers have developed an innovative technique using nanoparticles for soldering wounds, potentially revolutionizing wound closure methods. This groundbreaking approach offers precise temperature control and can be applied in minimally invasive surgery. The nanoparticles enable gentle laser soldering, … Read the full press release
(IN BRIEF) Basilea Pharmaceutica Ltd (SIX: BSLN), a biopharmaceutical company specializing in severe bacterial and fungal infection treatments, has announced an asset purchase agreement with Spexis AG (SIX: SPEX) for a preclinical antibiotics program aimed at combating Gram-negative bacteria, including … Read the full press release
(IN BRIEF) Evonik has been awarded the Responsible Care® Award by the European Chemical Industry Council (Cefic) in the “Safe and Sustainable Chemicals” category for its innovative glycolipid biosurfactants platform. The company’s glycolipid biosurfactants, developed using biotechnology, are recognized for … Read the full press release
(IN BRIEF) Accenture has announced a strategic investment through Accenture Ventures in QuantHealth, an AI-powered clinical trial design company specializing in cloud-based simulations for pharmaceutical and biotech companies. Using AI technology trained on extensive patient data and clinical trial information, … Read the full press release
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Investment, Ireland, Management, News, Pharma & Biotech, Science, Technology
Tagged Accenture, Accenture Ventures, AI technology, investment, Israel, Orr Inbar, partnership, Petra Jantzer, QuantHealth, sustainability, Tom Lounibos, USA
(IN BRIEF) The global life sciences industry has witnessed a resurgence in mergers and acquisitions (M&A) activity, with investments totaling $191 billion by December 10, 2023, compared to $142 billion in 2022. Although the number of completed deals decreased, the … Read the full press release
(IN BRIEF) Merck KGaA, Darmstadt, Germany, has entered into a licensing agreement with Inspirna, Inc. for ompenaclid (RGX-202), a first-in-class oral inhibitor of the creatine transport channel SLC6A8, and SLC6A8-targeting follow-on compounds, currently under Phase II evaluation for the second-line … Read the full press release
Posted in Business, Environment, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged colorectal cancer, Dr. Usman “Oz” Azam, ERBITUX, Inspirna, Merck KGaA, ompenaclid (RGX-202), partnership, sustainability, USA, Victoria Zazulina
(IN BRIEF) Novo Nordisk has announced separate research collaborations with Omega Therapeutics and Cellarity Inc. to explore innovative treatment approaches for obesity and MASH (Metabolic Associated Fatty Liver Disease). The collaboration with Omega aims to develop an epigenomic controller to … Read the full press release
Posted in Business, Denmark, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Cellarity Inc., Fabrice Chouraqui, innovative, Mahesh Karande, Marcus Schindler, MASH (Metabolic Associated Fatty Liver Disease), Novo Nordisk, Obesity, Omega Therapeutics, partnership, Paul Biondi, sustainability, treatments, USA
(IN BRIEF) QIAGEN, a leading provider of molecular diagnostics and life sciences solutions, is significantly expanding its operations in the Middle East region. In early 2024, the company will open its regional headquarters in Riyadh, Saudi Arabia, to strengthen its … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, Netherlands, News, Pharma & Biotech, Science, Technology
Tagged Middle East, Oman, partnership, QIAGEN, Riyadh HQ, Saudi Ministry of Health, Simona Grandits, sustainability, TB Screening Initiative
(IN BRIEF) AstraZeneca has announced its definitive agreement to acquire Gracell Biotechnologies Inc. (NASDAQ: GRCL), a global biopharmaceutical company specializing in cell therapies for cancer and autoimmune diseases. This strategic move aims to bolster AstraZeneca’s presence in the field of … Read the full press release
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged acquisition, Adrian Kemp, AstraZeneca, cell therapy, Dr. William Cao, Gracell Biotechnologies, Gracell's GC012F, partnership, Susan Galbraith, sustainability
(IN BRIEF) Sanofi has announced the discontinuation of the global clinical development program for tusamitamab ravtansine, following an interim analysis of the Phase 3 CARMEN-LC03 trial. The trial assessed tusamitamab ravtansine as a monotherapy in previously treated metastatic non-squamous non-small … Read the full press release
Posted in Business, France, Healthcare, Industrial, Management, News, Pharma & Biotech, Science
Tagged Dietmar Berger, NSCLC, Sanofi, Tusamitamab Ravtansine
(IN BRIEF) BioNTech and Duality Biologics have received Breakthrough Therapy designation from the FDA for their antibody-drug conjugate (ADC) candidate, BNT323/DB-1303. The designation is for the treatment of advanced endometrial cancer in patients who have progressed following immune checkpoint inhibitor … Read the full press release
Posted in Germany, Healthcare, Pharma & Biotech, Technology
Tagged advanced endometrial cancer, antibody-drug conjugate, BioNTech SE, BNT323, Breakthrough Therapy, DB-1303, Duality Biologics, DualityBio, endometrial cancer, FDA, HER2, Human Epidermal Growth Factor Receptor 2, Prof. Özlem Türeci M.D., uterine cancer, Vivian Gu M.D.
(IN BRIEF) Roche has announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) under Priority Review. The sBLA is for the reduction of allergic reactions, including anaphylaxis, caused by … Read the full press release
Posted in Business, Healthcare, Industrial, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged adults, allergic reactions, CHILDREN, FDA approval, Levi Garraway, Multiple Foods, Reducing, Roche, Xolair®
(IN BRIEF) Almirall S.A., a global pharmaceutical company specializing in medical dermatology, has confirmed its involvement in the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, taking place from January 8th to 11th, 2024. Carlos Gallardo, Chairman and CEO … Read the full press release
Posted in Business, Healthcare, Industrial, Management, Media, News, Pharma & Biotech, Science, Spain, Technology
Tagged 42nd Annual J.P. Morgan Healthcare Conference, Almirall, Carlos Gallardo, San Francisco
(IN BRIEF) BioNTech has achieved a significant milestone in expanding mRNA vaccine manufacturing in Africa with the inauguration of its Kigali site, which includes the first manufacturing unit known as BioNTainer. This move is part of BioNTech’s broader efforts to … Read the full press release
Posted in Business, Environment, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Africa, BioNTainer, BioNTech, Dr. Jean Kaseya, H.E. Macky Sall, H.E. Paul Kagame, H.E. Ursula von der Leyen, Hon. Annalena Baerbock, Moussa Faki Mahamat, mRNA Vaccine, Prof. Ugur Sahin, Rwanda, Sierk Poetting, vaccine
(IN BRIEF) GSK plc has announced positive results from Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial, evaluating the use of Jemperli (dostarlimab) in combination with standard chemotherapy and as maintenance therapy for patients with primary advanced or recurrent endometrial … Read the full press release
Posted in Business, Healthcare, Industrial, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged chomotherapy, dostarlimab, Endometrial Cancer Trial, GSK, Hesham Abdullah, RUBY, Zejula
(IN BRIEF) The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMAs) have jointly released a comprehensive Artificial Intelligence (AI) workplan outlining their collaborative strategy through 2028. This initiative aims to maximize the benefits of AI for stakeholders … Read the full press release
Posted in Artificial Intelligence (AI), Business, Environment, European Union, Financial, Healthcare, Industrial, Investment, Management, Netherlands, News, Pharma & Biotech, Science, Technology
Tagged 2028 Workplan, artificial-intelligence, EMA, HMAs, Medicines Regulation, partnership, sustainability
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
